These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Anti-inflammatory drug evaluation in ApoE-/- mice by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Sigovan M; Kaye E; Lancelot E; Corot C; Provost N; Majd Z; Breisse M; Canet-Soulas E Invest Radiol; 2012 Sep; 47(9):546-52. PubMed ID: 22864378 [TBL] [Abstract][Full Text] [Related]
4. Prospective comparison of (4S)-4-(3- Cheng MF; Huang YY; Ho BY; Kuo TC; Hsin LW; Shiue CY; Kuo HC; Jeng YM; Yen RF; Tien YW Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):810-820. PubMed ID: 30635754 [TBL] [Abstract][Full Text] [Related]
5. Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma. Hyun SH; Kim HS; Choi SH; Choi DW; Lee JK; Lee KH; Park JO; Lee KH; Kim BT; Choi JY Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1461-8. PubMed ID: 26872788 [TBL] [Abstract][Full Text] [Related]
6. PET/CT in brachytherapy early response evaluation of pancreatic ductal adenocarcinoma xenografts: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. Liu Y; Liu M; Liu X; Zhou Y Abdom Radiol (NY); 2019 Mar; 44(3):950-957. PubMed ID: 30315322 [TBL] [Abstract][Full Text] [Related]
7. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. Wang ZJ; Behr S; Consunji MV; Yeh BM; Ohliger MA; Gao K; Ko AH; Cinar P; Tempero MA; Collisson EA AJR Am J Roentgenol; 2018 Nov; 211(5):1010-1019. PubMed ID: 30063366 [TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
9. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma. Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875 [TBL] [Abstract][Full Text] [Related]
10. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Zhao Y; Cao J; Melamed A; Worley M; Gockley A; Jones D; Nia HT; Zhang Y; Stylianopoulos T; Kumar AS; Mpekris F; Datta M; Sun Y; Wu L; Gao X; Yeku O; Del Carmen MG; Spriggs DR; Jain RK; Xu L Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2210-2219. PubMed ID: 30659155 [TBL] [Abstract][Full Text] [Related]
11. Effects of ferumoxytol on quantitative PET measurements in simultaneous PET/MR whole-body imaging: a pilot study in a baboon model. Borra RJ; Cho HS; Bowen SL; Attenberger U; Arabasz G; Catana C; Josephson L; Rosen BR; Guimaraes AR; Hooker JM EJNMMI Phys; 2015 Dec; 2(1):6. PubMed ID: 26501808 [TBL] [Abstract][Full Text] [Related]
12. Intratumoral injection of gels containing losartan microspheres and (PLG-g-mPEG)-cisplatin nanoparticles improves drug penetration, retention and anti-tumor activity. Yu M; Zhang C; Tang Z; Tang X; Xu H Cancer Lett; 2019 Feb; 442():396-408. PubMed ID: 30439541 [TBL] [Abstract][Full Text] [Related]
13. Heterogeneity index evaluated by slope of linear regression on Kim YI; Kim YJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1995-2003. PubMed ID: 28634684 [TBL] [Abstract][Full Text] [Related]
14. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model. Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088 [TBL] [Abstract][Full Text] [Related]